Codeine — Discount Pricing

Other medications in Pain & Inflammation

• Dantrolene
• Diclofenac Gel
• Diclofenac Patch
• Diflunisal
• Dihydroergotamine
• Eletriptan
• Ergotamine
• Etodolac

What Codeine is approved for (FDA label)

Codeine sulfate tablets are indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. L i m i t ations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )] , reserve opioid analgesics, including codeine sulfate tablets, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Source: Read the full FDA label on DailyMed. Label effective date: January 16, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Codeine (FDA label)

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF CODEINE SULFATE TABLETS Addiction, Abuse, and Misuse Because the use of codeine sulfate tablets exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 ), Dosage and Administration ( 2.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of codeine sulfate tablets, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of codeine sulfate tablets are essential [see Warnings and Precautions ( 5.2 )] . Accidental Ingestion Accidental ingestion of even one dose of codeine sulfate tablets, especially by children, can result in a fatal overdose of codeine [see Warnings and Precautions ( 5.2 )] . Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Source: FDA prescribing information (DailyMed). Set ID: 5819bdf7-300e-45b8-8f3a-447b53656293. SPL document ID: aa8c1550-c22e-4945-8664-7a3d66523843. Label effective date: January 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Codeine (FDA label)

Each 15 mg tablet for oral administration contains 15 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “15” on the scored side and “LCI” on the other side. Each 30 mg tablet for oral administration contains 30 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “30” on the scored side and “LCI” on the other side. Each 60 mg tablet for oral administration contains 60 mg of Codeine Sulfate, USP. It is a white, round, uncoated tablet, scored on one side, debossed “1699” on the scored side and “LCI” on the other side.

Source: FDA prescribing information (DailyMed). Set ID: 5819bdf7-300e-45b8-8f3a-447b53656293. SPL document ID: aa8c1550-c22e-4945-8664-7a3d66523843. Label effective date: January 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Codeine (FDA label)

The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, Abuse, and Misuse [see Warnings and Precautions ( 5.1 )] Life-Threatening Respiratory Depression [see Warnings and Precautions ( 5.2 )] Interactions with Benzodiazepines and Other CNS Depressants [see Warnings and Precautions ( 5.3 )] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions ( 5.4 )] Ultra-Rapid Metabolism of Codeine and Other Risk Factors for Life-Threatening Respiratory Depression in Children [see Warnings and Precautions ( 5.6 )] Opioid-Induced Hyperalgesia and Allodynia [see Warnings and Precautions ( 5.8 )] Adrenal Insufficiency [see Warnings and Precautions ( 5.11 )] Severe Hypotension [see Warnings and Precautions ( 5.12 )] Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.14 )] Seizures [see Warnings and Precautions ( 5.15 )] Withdrawal [see Warnings and Precautions ( 5.16 )] The following adverse reactions associated with the use of codeine were identified in clinical studies or postmarketing reports.

Source: FDA prescribing information (DailyMed). Set ID: 5819bdf7-300e-45b8-8f3a-447b53656293. SPL document ID: aa8c1550-c22e-4945-8664-7a3d66523843. Label effective date: January 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Codeine (FDA label)

Codeine sulfate tablets are contraindicated for: All children younger than 12 years of age [see Warnings and Precautions ( 5.6 )] . Post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Warnings and Precautions ( 5.6 )] . Codeine sulfate tablets are also contraindicated in patients with: Significant respiratory depression [see Warnings and Precautions ( 5.2 )] . Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions ( 5.9 )] . Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions ( 5.10 ), Drug Interactions ( 7 )] . Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions ( 5.14 )] . Hypersensitivity to codeine (e.g., anaphylaxis) [see Adverse Reactions ( 6 )] . Children younger than 12 years of age.

Source: FDA prescribing information (DailyMed). Set ID: 5819bdf7-300e-45b8-8f3a-447b53656293. SPL document ID: aa8c1550-c22e-4945-8664-7a3d66523843. Label effective date: January 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Codeine (FDA label)

Opioid-Induced Hyperalgesia and Allodynia: Opioid-Induced Hyperalgesia (OIH) occurs when an opioid analgesic paradoxically causes an increase in pain, or an increase in sensitivity to pain. If OIH is suspected, carefully consider appropriately decreasing the dose of the current opioid analgesic, or opioid rotation. ( 5.8 ) Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Regularly evaluate closely, particularly during initiation and titration. ( 5.9 ) Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. ( 5.11 ) Severe Hypotension: Regularly evaluate during dosage initiation and titration. Avoid use of codeine sulfate tablets in patients with circulatory shock. ( 5.12 ) Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression.

Source: FDA prescribing information (DailyMed). Set ID: 5819bdf7-300e-45b8-8f3a-447b53656293. SPL document ID: aa8c1550-c22e-4945-8664-7a3d66523843. Label effective date: January 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Codeine (FDA label)

Table 1 includes clinically significant drug interactions with codeine sulfate tablets.

Source: FDA prescribing information (DailyMed). Set ID: 5819bdf7-300e-45b8-8f3a-447b53656293. SPL document ID: aa8c1550-c22e-4945-8664-7a3d66523843. Label effective date: January 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.